Mizuho Securities analyst Vamil Divan maintained a Buy rating on Biohaven Pharmaceutical Holding Co (NYSE:BHVN) on Wednesday, setting a price target of $92, which is approximately 6.93% below the present share price of $98.85.
Divan expects Biohaven Pharmaceutical Holding Co to post earnings per share (EPS) of -$4.27 for the third quarter of 2021.
The current consensus among 7 TipRanks analysts is for a Strong Buy rating of shares in Biohaven Pharmaceutical Holding Co, with an average price target of $104.5.
The analysts price targets range from a high of $140 to a low of $69.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $43.82 million and a net profit of -$235.67 million. The company's market cap is $6.43 billion.
According to TipRanks.com, Mizuho Securities analyst Vamil Divan is currently ranked with 1 stars on a 0-5 stars ranking scale, with an average return of -0.1% and a 52.71% success rate.
Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.